Clinical trial · Interventional
Preoperative High Protein vs Immunodiet in Surgical Cancer Patients
Preoperative Use of the High Protein ONS vs Immunoenhancing ONS in Gastrointestinal Cancer Patients Undergoing Surgery
NCT03980704CI-TRIAL-00052892Preop immunocompletedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Immunomodulating nutrition is supposed to reduce the number of complications and the legnth of the hospital stay during the postoperative period in patients after major gastrointestinal surgery. The aim of the study is to assess the clinical effect of immunomodulating oral nutrition in patients undergoing resection for gastrointestinal cancer in the group of well-nourished patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Colon | Malignant Colon Neoplasm | ALIAS | 0.90 |
| General Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IMPACT | Drug | — | UNRESOLVED |
| resource protein | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- High Protein
- description
- Provision of 400 ml per day of high protein oral nutritional supplements
- interventionNames
- Drug: resource protein
- type
- EXPERIMENTAL
- label
- Immuno ONS
- description
- Provision of 400 ml per day of immunostimulating oral nutritional supplements
- interventionNames
- Drug: IMPACT
Primary outcomes (1)
- measure
- Infectious complications
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * resectable GI cancer * written consent Exclusion Criteria: * inoperable GI cancer * known allergy to the drug
References
Publications (0)
Data not yet available
No reference posted for this study.